undamentalytics Newsletter
Sign in

Amylyx Pharmaceuticals, Inc. income statement

In fiscal 2025, Amylyx Pharmaceuticals, Inc. reported revenue of $0, down 100.0% on the year before and net income of −$145m, or −$1.53 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025
Revenue022381870
Cost of revenue—32560
Gross profit—19355810
Research and development449312810490
Selling, general and administrative3912718811463
Operating income−83−20139−315−153
Income before tax−88−19854−302−145
Income tax—15−00
Net income−88−19849−302−145
Diluted EPS−$13.35−$3.39$0.70−$4.43−$1.53
Diluted shares (average)7m58m70m68m95m
EBITDA−83−20140−314−153

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Amylyx Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Amylyx Pharmaceuticals, Inc.